After initially pursuing a career in three-dimensional design and moving into the third sector, I was drawn into the world of statistics due to a passion for disease research particularly in cancer patients.
At HDI I focus mainly on epidemiological studies, collaborating with charities and industry to highlight inequalities and support the development of new treatments.
Outside of work I’m a keen runner, who when not running, can often be found trying to convince others to take up the hobby.
Projects:
Ovarian cancer audit feasibility pilot
Cholangiocarcinoma (AMMF)
CORECT-R
Testing the Simulacrum
Real-world Standing Cohorts
Amy Zalin-Miller
Senior Health Data Analyst
Amy trained in epidemiology at the London School of Hygiene and Tropical Medicine. Whilst there she primarily focussed on non-communicable diseases, using the CPRD database to research treatment changes, adherence to guidelines, and associated factors in COPD patients.
She has experience of working with clinical data directly in an acute trust setting, where at Great Ormond Street she managed the clinical data and analysis for bone marrow transplants, oncology, infectious diseases, rheumatology and immunology.
Her in depth understanding of cancer datasets came from working within an NHS and Public Health England Partnership aiming to reduce inequalities in cancer across London.
These experiences led her to HDI where she works across several epidemiological studies. Her work includes developing real-world standing cohorts, where registration data are linked to treatment datasets to describe treatment pathways, outcomes and adverse effects as a population level comparator for novel therapeutics.
Education and awards:
2017-18: London School of Hygiene and Tropical Medicine
– MSc in Epidemiology (Distinction)
2014-15: Birkbeck University of London
– Graduate Certificate in Applied Statistics
2006-09: Northumbria University Newcastle
– BA Hons (First Class) Three Dimensional Design
Publications:
Cohort study to assess geographical variation in cholangiocarcinoma treatment in England
P47 Treatment pathways of patients diagnosed with hepatocellular carcinoma (HCC) after initial locoregional treatment in England
Regional variation in routes to diagnosis of cholangiocarcinoma in England from 2006 to 2017
Further information:
Linkedin profile